PFE250110C26000
- 0.96
- +0.05+5.49%
Pfizer Newsroom
Pfizer Is Maintained at Neutral by UBS
Pfizer Analyst Ratings
UBS Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
Truist Financial Sticks to Its Buy Rating for Pfizer (PFE)
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
Pfizer: Navigating Revenue Challenges and Opportunities With a Hold Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $29 to $33
Truist has lowered the Target Price for Pfizer to 32 dollars.
Pfizer Price Target Cut to $32.00/Share From $36.00 by Truist Securities
Pfizer Analyst Ratings
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $28 to $36
Wells Fargo Adjusts Price Target on Pfizer to $28 From $27, Keeps Equalweight Rating
Pfizer's Balanced Outlook: Hold Rating Amid Uncertainties and Growth Potential
Cautious Hold Rating for Pfizer Amidst Stable Near-Term Outlook and Long-Term Concerns
J.P. Morgan Reaffirms Their Hold Rating on Pfizer (PFE)
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $27
Pfizer (PFE) Gets a Hold From Wells Fargo
Goldman Sachs Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33